

DEC 29 2004

K043167

**510 (k) SUMMARY
AS REQUIRED BY SECTION 807.92(C)**

Identification: QuickScreen™ Benzodiazepines Test (Models 9025, 9026, 9027T, 9153 and 9195X)

Description: Immunoassay for the qualitative detection of Benzodiazepines in urine

Name Of Manufacturer: Phamatech
10151 Barnes Canyon Road
San Diego, California 92121, USA

Intended Use: The QuickScreen™ Benzodiazepines Test is a rapid, qualitative immunoassay for the detection of benzodiazepines in urine. The cutoff concentration for this test is 200 ng/ml. This assay is intended for professional use.

Technology: The QuickScreen™ Benzodiazepines Test, like many commercially available oxycodone screening test kits, qualitatively measures the presence of benzodiazepines by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the ABMC RapidOne BZD test (Kinderhook, NY). These devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / target analyte / antibody / complexes.

Performance: The product performance characteristics of the QuickScreen™ Benzodiazepines Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the QuickScreen™ Benzodiazepines Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of benzodiazepines in urine. Laboratory studies, using clinical specimens, produced a 97.9% correlation when compared to the predicate devices.

Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech QuickScreen™ Benzodiazepines Test is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe in the hands of the professional user.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

DEC 29 2004

Mr. Carl A. Mongiovi
Vice President
Phamatech, Inc.
10151 Barnes Canyon Road
San Diego, CA 92121

Re: k043167
Trade/Device Name: Phamatech QuickScreen™ Benzodiazepines Test
Models 9025, 9026 and 9027T
Phamatech QuickScreen™ Pro Multi Drug Screening Test
Models 9153T
Phamatech QuickScreen™ Pro Drug Cup Model 9195X
Regulation Number: 21 CFR 862.3170
Regulation Name: Benzodiazepine test system
Regulatory Class: Class II
Product Code: JXM
Dated: December 21, 2004
Received: December 22, 2004

Dear Mr. Mongiovi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 –

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Cornelia B. Rooks', with a stylized flourish at the end.

Cornelia B. Rooks, MA
Acting Director
Division of Chemistry and Toxicology
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): K043167.

Device Name: Phamatech QuickScreen™ Benzodiazepines Test Models 9025 , 9026 and 9027T

Indications for Use:

The QuickScreen Benzodiazepines Test is an in-vitro diagnostic screen that provides a preliminary result for the detection/presence of benzodiazepines in urine. It is intended for professional use only.

Prescription Use: X AND/OR
(Part 21 CFR 801 Subpart D)

Over the Counter Use: _____
(21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)


Division Sign-Off

Office of In Vitro Diagnostic
Device Evaluation and Safety

510(k) K043167

Page 1 of 1

INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): K043167.

Device Name: Phamatech QuickScreen™ Pro Multi Drug Screening Test Model 9153T

Indications for Use:


An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, benzodiazepines, barbiturates, methadone and THC in urine. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.

Prescription Use: X AND/OR
(Part 21 CFR 801 Subpart D)

Over the Counter Use:
(21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)


Division Sign-Off

Office of In Vitro Diagnostic
Device Evaluation and Safety

510(k) K043167

Page 1 of 1

INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): K 043167.

Device Name: Phamatech QuickScreen™ Pro Drug Cup Model 9195X

Indications for Use:

An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, benzodiazepines, barbiturates, methadone and THC in urine. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.

Prescription Use: X AND/OR
(Part 21 CFR 801 Subpart D)

Over the Counter Use:
(21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)


Division Sign-Off

Office of In Vitro Diagnostic
Device Evaluation and Safety

510(k) K043167

Page 1 of 1